SCHEMBL772510

SCHEMBL772510

CC1CC(I)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17231360 1.00
SCHEMBL20112968 0.96
SCHEMBL18231243 0.82
SCHEMBL18429987 0.82
SCHEMBL20115465 0.79
SCHEMBL20404505 0.78
SCHEMBL24348513 0.77
SCHEMBL21147433 0.77
SCHEMBL8524886 0.77
SCHEMBL18231811 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10292972-B1 Pharmaceutical composition for treating cancer and a method thereof KING ABDULAZIZ UNIVERSITY (SA) 2019-05-21 US disclosed
US-20190125732-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND A METHOD THEREOF KING ABDULAZIZ UNIVERSITY (SA) 2019-05-02 US disclosed
US-20180030207-A1 LINEAR CYCLODEXTRIN COPOLYMERS CALIFORNIA INSTITUTE OF TECHNOLOGY 2018-02-01 US disclosed
US-20160149005-A1 SEMICONDUCTOR DEVICE AND MANUFACTURING METHOD FOR SAME, CRYSTAL, AND MANUFACTURING METHOD FOR SAME FLOSFIA INC. (JP) 2016-05-26 US disclosed
EP-2692826-B1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2016-04-13 EP disclosed
EP-2692827-B1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2016-03-23 EP disclosed
US-9249163-B2 PDE10a inhibitors for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV. (BE) 2016-02-02 US disclosed
US-20150203634-A1 LINEAR CYCLODEXTRIN COPOLYMERS CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-07-23 US disclosed
US-20150062112-A1 Electronic Circuit, Display Device, Electronic Device, And Method For Driving Electronic Circuit SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2015-03-05 US disclosed
US-20140364414-A1 PDE 10a Inhibitors for the Treatment of Type II Diabetes JANSSEN PHARMACEUTICA, NV (BE) 2014-12-11 US disclosed
EP-2206736-A1 Polyglutamate-amino acid conjugates and methods Nitto Denko Corporation (JP) 2010-07-14 EP disclosed
US-20090297558-A1 Inactivated Influenza Virus Compositions DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH, GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2009-12-03 US disclosed
US-20090269325-A1 Methods for treating bleeding disorders using sulfated polysaccharides BAXTER INTERNATIONAL INC. (US) 2009-10-29 US disclosed
US-20090238763-A1 HIGH PENETRATION COMPOSITIONS AND USES THEREOF TECHFIELDS PHARMA CO., LTD. (CN) 2009-09-24 US disclosed
EP-2077290-A1 Polyglutamate-amino acid conjugates and methods Nitto Denko Corporation (JP) 2009-07-08 EP disclosed
EP-1969031-B1 POLYGLUTAMATE-AMINO ACID CONJUGATES AND METHODS NITTO DENKO CORP (JP) 2009-06-03 EP disclosed
US-20090076251-A1 FcGammaRIIB Specific Antibodies and Methods of Use Thereof MACROGENICS, INC. (US) 2009-03-19 US disclosed
US-20090036468-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-02-05 US disclosed
US-20090011464-A1 Humanized immunoglubulin reactive with alph4beta7 integrin MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-01-08 US disclosed
US-20080079064-A1 Semiconductor device and method of manufacturing the same MACRONIX INTERNATIONAL CO., LTD. (TW) 2008-04-03 US disclosed